Skip to content
HomeJohnson & Johnson to Host Live ESG Investor Update Webcast

Johnson & Johnson to Host Live ESG Investor Update Webcast

Webcast Will Highlight Progress Made to Advance a Healthier World for All and
Health for Humanity 2025 Goals

Live ESG Investor Update Webcast Scheduled for June 23, 2021 at 8:00 a.m. ET

Share Article
share to

NEW BRUNSWICK, N.J., May 24, 2021 – Johnson & Johnson (NYSE: JNJ) announced today it will host an Environmental, Social and Governance (ESG) Investor Update Webcast at 8:00 a.m. (Eastern Time) on June 23, 2021. The webcast will discuss progress made in advancing a healthier world for all and will outline the Company’s ESG management approach around its priority ESG topics. Leaders from across the enterprise will share progress the Company has made in each of their respective areas to help drive long-term value creation and strengthen our ability to respond to the needs and expectations of all stakeholders.

Discussed on the webcast will also be the Company’s recently announced Health for Humanity 2025 Goals (2025 Goals), which will be set forth in detail in the 2020 Health for Humanity Report. Grounded in the Company’s purpose to blend heart, science, and ingenuity to change the trajectory of human health, and guided by Our Credo, the 2025 Goals focus on ESG areas where Johnson & Johnson believes it will deliver the most impact.

The full set of 2025 Goals actively contribute to the United Nations 2030 Sustainable Development Goals (UN SDGs) and are aligned to the Company’s ESG priorities as identified through the Company’s Priority Topics Assessment, which informed the goal-setting process. For the full list of Johnson & Johnson’s 2025 Goals, including key performance indicators, please visit

2020 Health for Humanity Report
The webcast will also highlight our Health for Humanity Report, which provides an annual update on performance and progress across several ESG priority topics relevant to our business. The 2020 Health for Humanity Report will provide an update on the conclusion of the Company’s Health for Humanity 2020 Goals and UN SDGs Commitment, including details on the final year performance and progress. In addition, the 2020 Health for Humanity Report will include details on the Company’s 2025 Goals. The 2020 Health for Humanity Report, including a separate ESG Summary, will be available June 9, 2021 at

ESG Investor Update Webcast
Investors and other interested parties can pre-register for the webcast and submit questions in advance by visiting: Webcast materials which will be made available starting at 4:30 p.m. ET on June 22, 2021. Participants may also submit questions ahead of the webcast to The live webcast will begin at 8:00 a.m. ET on June 23, 2021. A replay will be available at

About Johnson & Johnson
At Johnson & Johnson, we believe good health is the foundation of vibrant lives, thriving communities and forward progress. That’s why for more than 130 years, we have aimed to keep people well at every age and every stage of life. Today, as the world’s largest and most broadly-based healthcare company, we are committed to using our reach and size for good. We strive to improve access and affordability, create healthier communities, and put a healthy mind, body and environment within reach of everyone, everywhere. We are blending our heart, science and ingenuity to profoundly change the trajectory of health for humanity. Learn more at Follow us at @JNJNews.

Forward-looking Statements
This press release contains “forward-looking statements” as defined in the Private Securities Litigation Reform Act of 1995 regarding, among other things: the Company’s future ESG performance, strategy, goals and commitments. The reader is cautioned not to rely on these forward-looking statements. These statements are based on current expectations of future events. If underlying assumptions prove inaccurate or known or unknown risks or uncertainties materialize, actual results could vary materially from the expectations and projections of Johnson & Johnson. Risks and uncertainties include, but are not limited to: risks related to the impact of the COVID-19 global pandemic, such as the scope and duration of the outbreak, government actions and restrictive measures implemented in response, material delays and cancellations of medical procedures, supply chain disruptions and other impacts to the business, or on the Company’s ability to execute business continuity plans, as a result of the COVID-19 pandemic, economic factors, such as interest rate and currency exchange rate fluctuations; competition, including technological advances, new products and patents attained by competitors; challenges inherent in new product research and development, including uncertainty of clinical success and obtaining regulatory approvals; uncertainty of commercial success for new and existing products; challenges to patents; the impact of patent expirations; the ability of the Company to successfully execute strategic plans; the impact of business combinations and divestitures; manufacturing difficulties or delays, internally or within the supply chain; product efficacy or safety concerns resulting in product recalls or regulatory action; significant adverse litigation or government action, including related to product liability claims; changes to applicable laws and regulations, including tax laws and global health care reforms; trends toward health care cost containment; changes in behavior and spending patterns of purchasers of health care products and services; financial instability of international economies and legal systems and sovereign risk; increased scrutiny of the health care industry by government agencies. A further list and descriptions of these risks, uncertainties and other factors can be found in Johnson & Johnson’s Annual Report on Form 10-K for the fiscal year ended January 3, 2021 including in the sections captioned “Cautionary Note Regarding Forward-Looking Statements” and “Item 1A. Risk Factors,” in the Company’s most recently filed Quarterly Report on Form 10-Q and the Company’s subsequent filings with the Securities and Exchange Commission. Copies of these filings are available online at, or on request from Johnson & Johnson. Any forward-looking statement made in this release speaks only as of the date of this release. Johnson & Johnson does not undertake to update any forward-looking statement as a result of new information or future events or developments.


Press Contacts:
Christina Chan
(732) 524-6297

Courtney Dugan
(347) 452-1061

Investor Contacts:
Lisa Romanko
(732) 524-2034

You are now leaving The site you’re being redirected to is a branded pharmaceutical website. Please click below to continue to that site.